异动解读 | 基因疗法公司研发利好 Krystal Biotech Inc.盘中大涨5.61%

异动解读
20 Feb

生物科技公司Krystal Biotech Inc.(KRYS)今日盘中大涨5.61%,引发市场广泛关注。

据分析,这主要得益于分析师机构Chardan Capital发布研究报告,维持该公司股票评级为"买入",并将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。

Krystal Biotech Inc.是一家专注于开发新型生物疫苗和基因疗法的临床阶段公司。公司最近在研发方面取得了一定进展,这增强了市场对其长期增长潜力的信心,成为分析师上调评级目标价的主要原因。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10